Zhi Zhang1, Cheng Chen1, Ying Fang1, Sheng Li1, Xiaohua Wang1, Lei Sun1, Guoren Zhou2, Jinjun Ye3. 1. Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & Nanjing Medical University Affiliated Cancer Hospital, 42 Bai Zi Ting Road, Nanjing, 210000, Jiangsu, China. 2. Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & Nanjing Medical University Affiliated Cancer Hospital, 42 Bai Zi Ting Road, Nanjing, 210000, Jiangsu, China. zhouguoren888@126.com. 3. Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & Nanjing Medical University Affiliated Cancer Hospital, 42 Bai Zi Ting Road, Nanjing, 210000, Jiangsu, China. jjye2004@163.com.
Abstract
BACKGROUND: Function of the immune system is correlated with the prognosis of the tumor. The effect of immune microenvironment on esophageal cancer (EC) development has not been fully investigated. METHODS: This study aimed to explore a prognostic model based on immune-related genes (IRGs) for EC. We obtained the RNA-seq dataset and clinical information of EC from the Cancer Genome Atlas (TCGA). RESULTS: We identified 247 upregulated IRGs and 56 downregulated IRGs. Pathway analysis revealed that the most differentially expressed IRGs were enriched in Cytokine-cytokine receptor interaction. We further screened 13 survival-related IRGs and constructed regulatory networks involving related transcription factors (TFs). Finally, a prognostic model was constructed with 9 IRGs (HSPA6, S100A12, CACYBP, NOS2, DKK1, OSM, STC2, NGPTL3 and NR2F2) by multivariate Cox regression analysis. The patients were classified into two subgroups with different outcomes. When adjusted with clinical factors, this model was verified as an independent predictor, which performed accurately in prognostic prediction. Next, M0 and M2 macrophages and activated mast cells were significantly enriched in high-risk group, while CD8 T cells and regulatory T cells (Tregs) were significantly enriched in low-risk group. CONCLUSIONS: Prognosis related IRGs were identified and a prognostic signature for esophageal cancer based on nine IRGs was developed.
BACKGROUND: Function of the immune system is correlated with the prognosis of the tumor. The effect of immune microenvironment on esophageal cancer (EC) development has not been fully investigated. METHODS: This study aimed to explore a prognostic model based on immune-related genes (IRGs) for EC. We obtained the RNA-seq dataset and clinical information of EC from the Cancer Genome Atlas (TCGA). RESULTS: We identified 247 upregulated IRGs and 56 downregulated IRGs. Pathway analysis revealed that the most differentially expressed IRGs were enriched in Cytokine-cytokine receptor interaction. We further screened 13 survival-related IRGs and constructed regulatory networks involving related transcription factors (TFs). Finally, a prognostic model was constructed with 9 IRGs (HSPA6, S100A12, CACYBP, NOS2, DKK1, OSM, STC2, NGPTL3 and NR2F2) by multivariate Cox regression analysis. The patients were classified into two subgroups with different outcomes. When adjusted with clinical factors, this model was verified as an independent predictor, which performed accurately in prognostic prediction. Next, M0 and M2 macrophages and activated mast cells were significantly enriched in high-risk group, while CD8 T cells and regulatory T cells (Tregs) were significantly enriched in low-risk group. CONCLUSIONS: Prognosis related IRGs were identified and a prognostic signature for esophageal cancer based on nine IRGs was developed.
Authors: Elfriede Bollschweiler; Patrick Plum; Stefan P Mönig; Arnulf H Hölscher Journal: Expert Opin Pharmacother Date: 2017-06-07 Impact factor: 3.889
Authors: A J Robert McGray; Robin Hallett; Dannie Bernard; Stephanie L Swift; Ziqiang Zhu; Florentina Teoderascu; Heather Vanseggelen; John A Hassell; Arthur A Hurwitz; Yonghong Wan; Jonathan L Bramson Journal: Mol Ther Date: 2013-10-23 Impact factor: 11.454
Authors: Pankaj Ahluwalia; Ashis K Mondal; Meenakshi Ahluwalia; Nikhil S Sahajpal; Kimya Jones; Yasmeen Jilani; Gagandeep K Gahlay; Amanda Barrett; Vamsi Kota; Amyn M Rojiani; Ravindra Kolhe Journal: Cancer Med Date: 2022-02-09 Impact factor: 4.452